BBI Brickell Biotech Inc

Price (delayed)

$0.235

Market cap

$28.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$10.76M

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium ...

Highlights
The debt has plunged by 100% YoY
Brickell Biotech's EPS has increased by 45% YoY and by 14% from the previous quarter
BBI's gross profit is down by 40% YoY but it is up by 19% QoQ
The company's revenue fell by 40% YoY but it rose by 19% QoQ
The net income has shrunk by 54% YoY
Brickell Biotech's equity has decreased by 45% YoY and by 36% from the previous quarter

Key stats

What are the main financial stats of BBI
Market
Shares outstanding
119.38M
Market cap
$28.05M
Enterprise value
$10.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.75
Price to sales (P/S)
58.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.47
Earnings
Revenue
$479,000
EBIT
-$39.84M
EBITDA
-$39.81M
Free cash flow
-$39.79M
Per share
EPS
-$0.42
Free cash flow per share
-$0.33
Book value per share
$0.13
Revenue per share
$0
TBVPS
$0.17
Balance sheet
Total assets
$20.79M
Total liabilities
$4.74M
Debt
$0
Equity
$16.05M
Working capital
$15.95M
Liquidity
Debt to equity
0
Current ratio
4.36
Quick ratio
3.65
Net debt/EBITDA
0.43
Margins
EBITDA margin
-8,311.5%
Gross margin
100%
Net margin
-8,325.5%
Operating margin
-8,486.2%
Efficiency
Return on assets
-153.7%
Return on equity
-191.6%
Return on invested capital
N/A
Return on capital employed
-248.3%
Return on sales
-8,317.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBI stock price

How has the Brickell Biotech stock price performed over time
Intraday
101.72%
1 week
93.73%
1 month
47.34%
1 year
-74.73%
YTD
2.66%
QTD
-12.15%

Financial performance

How have Brickell Biotech's revenue and profit performed over time
Revenue
$479,000
Gross profit
$479,000
Operating income
-$40.65M
Net income
-$39.88M
Gross margin
100%
Net margin
-8,325.5%
BBI's operating margin has plunged by 160% YoY but it is up by 15% from the previous quarter
The net margin has plunged by 156% YoY but it has grown by 15% from the previous quarter
The operating income has shrunk by 57% YoY
The net income has shrunk by 54% YoY

Growth

What is Brickell Biotech's growth rate over time

Valuation

What is Brickell Biotech stock price valuation
P/E
N/A
P/B
1.75
P/S
58.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.47
Brickell Biotech's EPS has increased by 45% YoY and by 14% from the previous quarter
The price to book (P/B) is 62% lower than the last 4 quarters average of 2.3 and 28% lower than the 5-year quarterly average of 1.2
Brickell Biotech's equity has decreased by 45% YoY and by 36% from the previous quarter
BBI's P/S is 76% lower than its last 4 quarters average of 122.6 and 6% lower than its 5-year quarterly average of 30.8
The company's revenue fell by 40% YoY but it rose by 19% QoQ

Efficiency

How efficient is Brickell Biotech business performance
Brickell Biotech's ROS has plunged by 156% YoY but it has increased by 15% from the previous quarter
The company's return on assets has shrunk by 88% YoY and by 19% QoQ
The ROE has plunged by 76% YoY and by 17% from the previous quarter

Dividends

What is BBI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBI.

Financial health

How did Brickell Biotech financials performed over time
BBI's total liabilities has plunged by 51% YoY
Brickell Biotech's total assets has decreased by 46% YoY and by 30% from the previous quarter
The debt is 100% less than the equity
The debt has plunged by 100% YoY
Brickell Biotech's debt to equity has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.